KRAS G12V

CI-VAR-00001619Explore in graph →CIViC 147

Curated evidence

Evidence by cancer (2 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–2 of 2 evidence items across 2 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Malignant Neoplasm1
KRAS G12V	EFTX-G12V	Predictive	D	Supports Sensitivity Response	3	submitted	EID13114 EFTX-G12V is an EGFR-directed, chemically modified siRNA designed to selectively target KRAS G12V. EFTX-G12V utilizes EGFR-mediated delivery to target tumor cells, taking advantage of the elevated EGF… (full text at CIViC) PMID 40541192 · Stanland et al., 2025 · Open in CIViC	civic
Solid Tumors, Advanced1unmapped disease
KRAS G12V	MRNA Vaccine + PembrolizumabCombination	Predictive	C	Supports Sensitivity Response	2	submitted	EID12180 This paper presents two case studies on patients with advanced solid tumours harbouring the KRAS G12V mutation, treated with a combination of an mRNA vaccine targeting KRAS G12V and pembrolizumab. Pa…

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.